Peptide receptor radionuclide therapy with 177Lu-octreotate in patients with foregut carcinoid tumours of bronchial, gastric and thymic originReportar como inadecuado




Peptide receptor radionuclide therapy with 177Lu-octreotate in patients with foregut carcinoid tumours of bronchial, gastric and thymic origin - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

European Journal of Nuclear Medicine and Molecular Imaging

, Volume 34, Issue 8, pp 1219–1227

First Online: 27 January 2007Received: 04 September 2006Accepted: 03 December 2006

Abstract

PurposeForegut carcinoid tumours have a different embryological origin than other gastroenteropancreatic neuroendocrine tumours GEP NETs. In the total group of GEP NETs n = 131, treatment with Lu-octreotate resulted in tumour remission in 47% of patients, with a median time to progression TTP of >36 months. As patients with foregut carcinoids may respond differently, we here present the effects of this treatment in a subgroup of patients with foregut carcinoids of bronchial, gastric or thymic origin.

MethodsNine patients with bronchial, five with gastric and two with thymic carcinoids were treated. All patients had metastasised disease. The intended cumulative dose of Lu-octreotate was 22.2–29.6 GBq. Southwest Oncology Group criteria were used for response evaluation.

ResultsBronchial carcinoids: Five patients had partial remission, one had minor response MR, tumour size reduction: ≥25%, <50%, two had stable disease SD and one had progressive disease PD. Median TTP was 31 months. Gastric carcinoids: One patient had complete remission, one had MR and two had SD, including one with PD at baseline. One patient developed PD. Thymic carcinoids: One patient had SD. In the other patient, disease remained progressive. All patients: Overall remission rate was 50%, including MR.

ConclusionLu-octreotate treatment can be effective in patients with bronchial and gastric carcinoids. Its role in thymic carcinoids cannot be determined yet because of the limited number of patients. The overall remission rate of 50% in patients with the studied foregut carcinoids is comparable to that in the total group of GEP NETs.

KeywordsLu-octreotate Foregut carcinoid Bronchial carcinoid Gastric carcinoid Thymic carcinoid  Download fulltext PDF



Autor: Martijn van Essen - Eric P. Krenning - Willem H. Bakker - Wouter W. de Herder - Maarten O. van Aken - Dik J. Kwekkeb

Fuente: https://link.springer.com/



DESCARGAR PDF




Documentos relacionados